Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureKan Yonemori, Akihiro Hirakawa, Masashi Ando, Taizo Hirata, Chikako Shimizu, Noriyuki Katsumata, Kenji Tamura
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Risks and benefits of phase 1 oncology trials, 1991 through 2002
10.1056/nejmsa042220 · 2005
Responses and toxic deaths in phase I clinical trials
10.1093/oxfordjournals.annonc.a057716 · 1990
Therapeutic response in phase I trials of antineoplastic agents
1986
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials
10.1023/a:1008368319526 · 2000
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs. new noncytotoxic agents
10.1038/sj.bjc.6601218 · 2003
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials
10.1001/jama.292.17.2130 · 2004
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
10.1038/sj.bjc.6604218 · 2008
Pharmaceutical research and development
2010
The advisory process for anticancer drug regulation: a global perspective
10.1093/annonc/mdj099 · 2006
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
2003
Annual Report on Health
2004
Unresolved referenced work
Kept as external metadata until matched
Prognostic factors for survival in patients treated in phase I clinical trials
10.1002/1097-0142(19941001)74:7<1965::aid-cncr2820740723>3.0.co;2-1 · 1994
Participants in phase 1 oncology research trials: are they vulnerable?
10.1001/archinternmed.2007.6 · 2008
Prognostic factors among cancer patients with good performance status screened for phase I trials
10.1007/s10637-007-9088-x · 2008
Cancer statistics
10.3322/canjclin.50.1.7 · 2000
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review
10.1002/cncr.23157 · 2008
Systemic review of barriers to the recruitment of older patients with cancer onto clinical trials
10.1200/jco.2005.00.141 · 2005
Enrollment of elderly patients in clinical trial for cancer drug registration: a 7-year experience by the US Food and Drug Administration
10.1200/jco.2004.02.175 · 2004
Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD
10.7326/0003-4819-104-6-757 · 1986
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies
10.1002/cncr.20615 · 2004
A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index
10.1111/j.1365-2141.2005.05508.x · 2005
Unresolved referenced work
2009
No additional external references are available.